Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Sees Large Increase in Short Interest

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a significant increase in short interest in January. As of January 30th, there was short interest totaling 619,061 shares, an increase of 125.8% from the January 15th total of 274,164 shares. Currently, 44.2% of the shares of the company are sold short. Based on an average trading volume of 13,995,251 shares, the short-interest ratio is currently 0.0 days. Based on an average trading volume of 13,995,251 shares, the short-interest ratio is currently 0.0 days. Currently, 44.2% of the shares of the company are sold short.

Institutional Trading of Shuttle Pharmaceuticals

An institutional investor recently bought a new position in Shuttle Pharmaceuticals stock. Connective Capital Management LLC bought a new stake in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 100,535 shares of the company’s stock, valued at approximately $357,000. Connective Capital Management LLC owned about 9.40% of Shuttle Pharmaceuticals as of its most recent SEC filing. 4.58% of the stock is currently owned by institutional investors and hedge funds.

Shuttle Pharmaceuticals Stock Up 2.7%

Shares of NASDAQ:SHPH traded up $0.03 during midday trading on Thursday, reaching $1.15. 20,949 shares of the company traded hands, compared to its average volume of 5,394,485. Shuttle Pharmaceuticals has a 12 month low of $1.09 and a 12 month high of $17.70. The firm’s fifty day moving average price is $1.79 and its two-hundred day moving average price is $2.74. The firm has a market capitalization of $1.84 million, a price-to-earnings ratio of -0.10 and a beta of -1.02.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its quarterly earnings data on Thursday, November 13th. The company reported ($1.05) EPS for the quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on SHPH shares. Weiss Ratings restated a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Shuttle Pharmaceuticals has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .